Top-Rated StocksTop-RatedNASDAQ:IMCR Immunocore (IMCR) Stock Price, News & Analysis → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Free IMCR Stock Alerts $60.49 -0.34 (-0.56%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$59.55▼$61.3750-Day Range$60.14▼$75.3652-Week Range$42.21▼$76.98Volume557,007 shsAverage Volume522,294 shsMarket Capitalization$3.01 billionP/E RatioN/ADividend YieldN/APrice Target$75.15 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Immunocore alerts: Email Address Immunocore MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside24.2% Upside$75.15 Price TargetShort InterestBearish8.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.10Based on 10 Articles This WeekInsider TradingSelling Shares$305,769 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.58) to ($1.93) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.53 out of 5 starsMedical Sector741st out of 947 stocksBiological Products, Except Diagnostic Industry130th out of 159 stocks 3.4 Analyst's Opinion Consensus RatingImmunocore has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 12 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $75.15, Immunocore has a forecasted upside of 24.2% from its current price of $60.49.Amount of Analyst CoverageImmunocore has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.71% of the float of Immunocore has been sold short.Short Interest Ratio / Days to CoverImmunocore has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Immunocore has recently increased by 9.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmunocore does not currently pay a dividend.Dividend GrowthImmunocore does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMCR. Previous Next 2.8 News and Social Media Coverage News SentimentImmunocore has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Immunocore this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for IMCR on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Immunocore to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunocore insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $305,769.00 in company stock.Percentage Held by InsidersOnly 5.70% of the stock of Immunocore is held by insiders.Percentage Held by Institutions73.45% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immunocore are expected to decrease in the coming year, from ($1.58) to ($1.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunocore is -52.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunocore is -52.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunocore has a P/B Ratio of 8.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About Immunocore Stock (NASDAQ:IMCR)Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Read More IMCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMCR Stock News HeadlinesMarch 18, 2024 | americanbankingnews.comFY2024 EPS Estimates for Immunocore Holdings plc (NASDAQ:IMCR) Lifted by Cantor FitzgeraldMarch 16, 2024 | finance.yahoo.comIMCR Apr 2024 45.000 putMarch 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 16, 2024 | finance.yahoo.comIMCR Apr 2024 95.000 callMarch 11, 2024 | markets.businessinsider.comCastle Biosciences: A Strong Buy on Genomic Diagnostic Leadership and Market Growth PotentialMarch 11, 2024 | americanbankingnews.comImmunocore Holdings plc (NASDAQ:IMCR) Receives Average Recommendation of "Moderate Buy" from BrokeragesMarch 11, 2024 | americanbankingnews.comResearch Analysts Offer Predictions for Immunocore Holdings plc's Q3 2024 Earnings (NASDAQ:IMCR)March 9, 2024 | americanbankingnews.comAnalysts Offer Predictions for Immunocore Holdings plc's Q1 2024 Earnings (NASDAQ:IMCR)March 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 6, 2024 | markets.businessinsider.comBuy Rating on Immunocore Holdings: Robust Financials and Promising Pipeline Signal GrowthMarch 5, 2024 | globenewswire.comImmunocore presented two posters at CROI 2024March 1, 2024 | seekingalpha.comImmunocore Holdings plc (IMCR) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | globenewswire.comImmunocore to present at upcoming investor conferencesFebruary 29, 2024 | markets.businessinsider.comKey Takeaways From Immunocore Hldgs Analyst RatingsFebruary 29, 2024 | finance.yahoo.comImmunocore Holdings plc (NASDAQ:IMCR) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comImmunocore Holdings PLC (IMCR) Reports Strong Revenue Growth Amidst Expansion and Clinical ...February 28, 2024 | msn.comImmunocore GAAP EPS of -$0.40 misses by $0.13, revenue of $70.16M beats by $1.79MFebruary 28, 2024 | globenewswire.comImmunocore reports fourth quarter and full year 2023 financial results and provides a business updateFebruary 27, 2024 | msn.comImmunocore FY 2023 Earnings PreviewFebruary 24, 2024 | investing.comImmunocore Holdings Ltd (IMCR)February 22, 2024 | globenewswire.comImmunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trialFebruary 21, 2024 | finance.yahoo.comImmunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024February 21, 2024 | globenewswire.comImmunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024February 14, 2024 | finance.yahoo.comZacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma BiotechnologyFebruary 3, 2024 | morningstar.comImmunocore Holdings PLC ADR IMCRFebruary 3, 2024 | msn.comImmunocore Holdings Announces Offering Pricing DetailsFebruary 1, 2024 | finance.yahoo.comDELFI Diagnostics Announces Availability of New Fragmentome-Based Cancer Treatment Monitoring AssaySee More Headlines Receive IMCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/19/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IMCR CUSIPN/A CIK1671927 Webwww.immunocore.com Phone44-12-3543-8600FaxN/AEmployees408Year FoundedN/APrice Target and Rating Average Stock Price Target$75.15 High Stock Price Target$91.00 Low Stock Price Target$16.00 Potential Upside/Downside+24.2%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,290,000.00 Net Margins-22.48% Pretax Margin-24.41% Return on Equity-15.78% Return on Assets-9.91% Debt Debt-to-Equity Ratio0.13 Current Ratio3.80 Quick Ratio3.77 Sales & Book Value Annual Sales$249.43 million Price / Sales12.08 Cash FlowN/A Price / Cash FlowN/A Book Value$7.42 per share Price / Book8.15Miscellaneous Outstanding Shares49,820,000Free Float46,981,000Market Cap$3.01 billion OptionableOptionable Beta0.90 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Bahija Jallal Ph.D. (Age 62)CEO & Director Comp: $1.42MMr. Brian R. Di Donato M.B.A. (Age 57)CFO & Head of Strategy Ms. Annelise Vuidepot Ph.D.CTO and Head of Pipeline & Platform ResearchClayton RobertsonHead of Investor RelationsMs. Lily Margaret HepworthGeneral Counsel & Company SecretaryMs. Amy Judge-PreinChief Compliance OfficerMr. Sébastien DesprezHead of CommunicationsMs. Tina St. Leger (Age 56)Chief Human Resources Officer & Director Dr. David Berman M.D. (Age 53)Ph.D., Head of Research & Development Ms. Debra NielsenChief of StaffMore ExecutivesKey CompetitorsBeam TherapeuticsNASDAQ:BEAMDenali TherapeuticsNASDAQ:DNLINeumora TherapeuticsNASDAQ:NMRAImmunityBioNASDAQ:IBRXApogee TherapeuticsNASDAQ:APGEView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 399,201 shares on 3/5/2024Ownership: 8.812%Goldman Sachs Group Inc.Sold 33,833 shares on 3/1/2024Ownership: 0.099%Great Point Partners LLCBought 2,083 shares on 2/15/2024Ownership: 0.599%Pier Capital LLCSold 1,220 shares on 2/15/2024Ownership: 0.176%Virtus ETF Advisers LLCSold 161 shares on 2/15/2024Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions IMCR Stock Analysis - Frequently Asked Questions Should I buy or sell Immunocore stock right now? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunocore in the last twelve months. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IMCR shares. View IMCR analyst ratings or view top-rated stocks. What is Immunocore's stock price target for 2024? 14 brokers have issued twelve-month price targets for Immunocore's shares. Their IMCR share price targets range from $16.00 to $91.00. On average, they predict the company's share price to reach $75.15 in the next year. This suggests a possible upside of 24.2% from the stock's current price. View analysts price targets for IMCR or view top-rated stocks among Wall Street analysts. How have IMCR shares performed in 2024? Immunocore's stock was trading at $68.32 at the beginning of 2024. Since then, IMCR shares have decreased by 11.5% and is now trading at $60.49. View the best growth stocks for 2024 here. Are investors shorting Immunocore? Immunocore saw a increase in short interest during the month of February. As of February 29th, there was short interest totaling 4,230,000 shares, an increase of 9.6% from the February 14th total of 3,860,000 shares. Based on an average daily trading volume, of 494,300 shares, the days-to-cover ratio is presently 8.6 days. Currently, 8.7% of the company's shares are sold short. View Immunocore's Short Interest. When is Immunocore's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our IMCR earnings forecast. How were Immunocore's earnings last quarter? Immunocore Holdings plc (NASDAQ:IMCR) released its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.12. The business had revenue of $70.16 million for the quarter, compared to analyst estimates of $53.25 million. Immunocore had a negative trailing twelve-month return on equity of 15.78% and a negative net margin of 22.48%. The firm's revenue was up 22.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.63) EPS. What ETFs hold Immunocore's stock? ETFs with the largest weight of Immunocore (NASDAQ:IMCR) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP) and Range Cancer Therapeutics ETF (CNCR).BlackRock Future Health ETF (BMED). When did Immunocore IPO? (IMCR) raised $199 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,300,000 shares at a price of $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies acted as the underwriters for the IPO. Who are Immunocore's major shareholders? Immunocore's stock is owned by many different retail and institutional investors. Top institutional investors include Wellington Management Group LLP (8.81%), Price T Rowe Associates Inc. MD (6.02%), Bellevue Group AG (1.99%), Fiera Capital Corp (1.73%), Braidwell LP (1.25%) and Principal Financial Group Inc. (0.99%). View institutional ownership trends. How do I buy shares of Immunocore? Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMCR) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.